from Integrative Therapeutics, LLC and to theTerms of Use. I understand that my information will be used as described in thePrivacy Policy. I understand I can change my mind at any time by clicking the unsubscribe link in the footer of any email I receive from Integrative Therapeutics, LLC....
I understand that my information will be used as described in the Privacy Policy. I understand I can change my mind at any time by clicking the unsubscribe link in the footer of any email I receive from Integrative Therapeutics, LLC.
I understand that my information will be used as described in the Privacy Policy. I understand I can change my mind at any time by clicking the unsubscribe link in the footer of any email I receive from Integrative Therapeutics, LLC.
No Magic Formula to Grow Integrative Health Companies: Start Here Instead Whether your business is a medical practice, supplement company, pharmacy, technology platform, nonprofit organization, or provider of other goods or services, one thing holds true: there is no single, magic ...
Recurrent ovarian cancer patients, especially those resistant to platinum, lack effective curative treatments. To address this, we conducted a phase 2 clinical trial (NCT02853318) combining pembrolizumab with bevacizumab, to increase T cell infiltration
CCM Biosciences Scientists Discover First-in-Class Longevity Therapeutics Applying a newly identified biophysical mechanism of enzyme activation, researchers at the longevity therapeutics division of the diversified biopharmaceutical company CCM Biosciences, Inc., have discovered and characterized first-in-class...
Assessing the clinical utility of NGS testing in oncology remains challenging for several reasons: (1) the definition of clinically actionable alterations is dynamic as new therapeutics emerge; (2) patients’ tumors often harbor numerous alterations, with uncertainty surrounding which events are most imp...
Clinical Pharmacology & Therapeutics, 89(2), 183–188. Article Google Scholar Kale, D., & Little, S. (2007). From imitation to innovation: The evolution of R&D capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management, 19(5), 589–...
Kwon holds patents for methods regarding anti-CD 137 and adaptive CTL therapeutics; Valter D. Longo has an equity interest in L-Nutra, a company that develops medical food; Kapil Mehta is a scientific advisor to Lifecare Innovations, and holds India Patent 8.765.797, TG2 inhibitors and uses...
Statins, which are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are the cornerstone in the management of dyslipidemia and are frequently first-line therapeutics [9]. Robust evidence demonstrates that statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9...